美國臨床實驗室服務市場成長機會及至2030年預測

受專業檢測的擴展、數位化工作流程創新以及對基於價值的醫療服務的需求推動。

由於美國人口老化、患者對檢測益處的認知提高、檢測成本下降、用於疾病檢測和管理的先進和專業檢測方法的開發、人們越來越意識到早期檢測和預防是降低醫療保健成本的一種手段，以及遺傳學、基因組學和個性化醫療領域的持續研究和開發，臨床檢測行業預計將繼續經歷檢測量的增加。

美國醫療保健支出約佔其GDP的18%。醫療保健價值鏈上的參與者面臨著受多種趨勢影響的動態環境，包括人口老化、慢性病負擔加重、監管挑戰、整個醫療保健鏈的整合、向基於價值和責任醫療模式的轉變、支付方與提供方的整合、數據獲取管道的更新和擴展、創新和技術，以及消費者參與度和期望值的提高。

在疫情後檢測需求正常化、門診病人增加以及先進的分子和基因組檢測融入常規診療的推動下，2024年和2025年的成長勢頭將持續加速。從2026年開始，隨著支付方主導的使用限制和高通量效率的逐步落實，預計成長速度將放緩至4-5%左右，與更新後的預測軌跡相符。儘管《保護醫療保險取得法案》（PAMA）帶來的價格壓力仍然存在，但支付方的報銷越來越與臨床效用和檢測價值掛鉤。為了確保獲利能力，實驗室（尤其是醫院附屬實驗室和中型區域實驗室）被迫專注於營運擴充性、檢測專案最佳化和數位化工作流程效率的提升，以維持盈利。

報告摘要：美國醫療和診斷檢測服務市場

美國醫療和診斷檢測服務市場預計在2024年達到1308.8億美元，到2030年將達到1751.3億美元，2024年至2030年的複合年成長率為5.0%。市場成長的促進因素包括人口老化導致檢測量增加、慢性病盛行率上升以及實驗室診斷在預防保健和基於價值的醫療保健模式中的作用日益增強。

關鍵市場趨勢與洞察

• 在全國物流網路和各種檢測項目的支持下，獨立實驗室和參考實驗室在臨床實驗室服務市場中佔據了巨大的檢測量。
• 美國臨床實驗室服務市場對常規診斷測試以及分子診斷、腫瘤檢測和基因檢測的需求不斷成長。
• 自動化、LIS-EHR 整合和 AI 驅動的工作流程最佳化正在提高大中型實驗室的檢測結果報告時間和營運效率。
• 美國臨床實驗室服務市場正在經歷持續的整合，大規模國家實驗室尋求透過收購和加強與醫院的合作來擴大業務。
• 零售診所、行動診斷和家庭檢體採集模式正在擴大患者的就醫途徑和便利性，從而支持提高檢測利用率。

市場規模及預測

• 2024年市場規模：1,308.8億美元
• 2030年市場規模預測：1751.3億美元
• 複合年成長率（2024-2030年）：5.0%
• 美國：擁有全國性檢測網路的單一市場

美國醫療保健系統對診斷測試的持續依賴，以及技術應用和服務模式的創新，預計將在整個預測期內支持美國醫療和診斷測試服務市場的持續成長。

市場概覽及趨勢：美國醫療與診斷檢測服務市場

美國醫療和診斷檢測服務市場幾乎貫穿整個醫療保健流程的每項臨床決策。檢測有助於篩檢、診斷、治療方案選擇和疾病監測，這使得臨床實驗室服務市場成為現代醫療保健不可或缺的一部分。由於人口老化、慢性病負擔加重以及基於價值的醫療模式下診斷檢測的廣泛應用，市場需求持續成長。

塑造美國臨床實驗室服務市場的一個關鍵結構性趨勢是轉向專業化和高度複雜的檢測方向。分子診斷、基因組學、腫瘤檢測和伴隨診斷擴大被用於指南個人化治療策略。常規檢測的檢測量保持穩定，而專業診斷則推動了檢測量的增量成長和臨床相關性的提升。

自動化數位化正在改變實驗室的運作方式。先進的機器人技術、實驗室資訊系統 (LIS) 和人工智慧驅動的工作流程工具正在加快檢測結果的周轉速度，並減少對人工的依賴。鑑於美國醫療和診斷檢測服務市場持續面臨勞動力短缺，這些投資顯得尤為重要。

另一個重要趨勢是檢測的集中化。由於規模經濟和更廣泛的檢測項目，獨立檢測機構和參考實驗室正在佔據越來越多的外包檢測佔有率。雖然整合帶來了成本效益，但也加劇了美國臨床實驗室服務市場的競爭。

醫療保健的消費化也正在影響需求。零售診所、行動診斷和居家檢體採集正在擴大常規檢測和預防性護理的覆蓋範圍。這些模式是對傳統醫院服務的補充，並正在重塑臨床實驗室服務市場的病患參與模式。

總體而言，市場正在朝著更自動化、數據驅動和以患者為中心的診斷生態系統發展。

分析範圍：美國醫療與診斷檢測服務市場

本分析檢驗了美國醫療和診斷測試服務市場，重點關注美國境內提供的實驗室測試服務。本研究評估了對血液、組織、尿液和其他生物檢體進行的診斷測試，以支持預防、診斷和治療領域的臨床決策。

報告涵蓋醫院檢查室、獨立實驗室和參考實驗室、醫生診所檢查室，以及新興的零售和居家檢測模式。美國臨床實驗室服務市場包括常規檢測和特殊檢測服務，但不包括檢測設備製造和試劑銷售。

本研究涵蓋近幾年至2030年，以2024年為基準年，2030年為預測終點。市場規模和預測均以美元計價。

調查方法整合了二手研究、醫療服務使用資料、監管審查和專家意見。我們的市場預測反映了檢測量趨勢、報銷趨勢以及整體臨床實驗室服務市場的結構性變化。為了保持分析的一致性，我們刻意不提供按細分市場分類的收入預測。

市場區隔分析：美國醫療與診斷檢測服務市場

美國醫療和診斷檢測服務市場按提供者類型和檢測服務類別進行細分，反映了更廣泛的臨床檢測服務市場中多樣化的營運模式和臨床角色。

按服務提供者進行細分

按提供者類型分類，美國臨床檢測服務檢查室包括醫院檢查室、醫生擁有的檢查室(POL)、獨立實驗室和參考檢查室、專業檢查室和其他檢測機構。

院內檢查室處理最大的檢測量，並直接整合到醫院系統中，為住院患者照護、急診診斷和複雜的臨床工作流程提供支援。這些檢查室通常隸屬於大規模醫療機構或大學附屬醫院，因此能夠快速出具檢測結果並與臨床團隊密切合作。

醫生自營檢查室（POL）設在醫生診所和專科診所內，例如泌尿系統、婦科和內分泌科。雖然以機構數量計算，POL是最常見的檢查室類型，但其檢測量僅佔總檢測量的不到10%。這些機構專注於小批量常規檢測和就地檢驗，可即時獲得結果。大規模的POL網路通常會將檢體送到中心檢查室進行更進階的檢測。

獨立實驗室、參考實驗室和專業實驗室的業務範圍遍及廣闊的地域，並管理多個檢測設施。參考實驗室提供全面的檢測項目，並能處理高通量檢測；而專業實驗室則專注於腫瘤學、遺傳學和分子檢測等高階診斷。這些機構在美國臨床實驗室服務市場中扮演著核心角色，為醫院和病患實驗室（POL）的外包檢測提供支援。

其他檢測機構包括零售診所、行動診斷中心、養老院和居家醫療機構。這些機構主要提供常規和預防性檢測。此類服務大多為自費，無法獲得聯邦醫療保險（Medicare）的全額報銷，因此對醫療保健總收入的貢獻有限。

檢驗服務分類

根據服務類型，臨床檢測服務市場分為常規檢測服務和特殊檢測服務。

常規檢測服務包括常見的診斷程序，如血液化學分析、血液常規檢查、尿液檢查等。這些檢測構成了美國醫療和診斷檢測服務市場診斷量的基礎。

專業檢測服務包括細胞遺傳學檢測、分子診斷、次世代定序(NGS) 和全EXOME定序(WES) 等高階診斷技術。血液凝固檢驗、自體免疫檢測和癌症生物標記檢測等半專業服務也屬於此類。專業檢測的成長反映了精準醫療和先進臨床決策支援日益成長的需求。

收入與預測：美國醫療與診斷檢測服務市場

隨著自動化、產業整合以及向價值醫療模式的轉變重塑產業經濟，美國醫療和診斷檢測服務市場持續發展。營收預測顯示，該市場規模將在2024年達到1,308.8億美元，並在2030年達到1,751.3億美元。這意味著2024年至2030年的年複合成長率（CAGR）為5.0%，展現出穩定擴張的趨勢，也印證了檢測在美國醫療保健系統臨床決策中發揮的關鍵作用。

美國臨床實驗室服務市場的收入成長主要受人口老化、慢性病盛行率上升以及預防保健和後續觀察中診斷檢測應用日益廣泛等因素推動，從而導致檢測量增加。同時，由於《病患保護與平價醫療法案》(PAMA) 的報銷削減、人事費用上升以及對檢查室自建檢測 (LDT) 的監管審查加強，檢查室正經歷結構性變革以應對利潤壓力。

大規模全國性網路實驗室和醫院附屬實驗室正透過合併、數位整合和人工智慧驅動的流程自動化加速擴張，以提高營運效率和規模。對自動化、實驗室資訊系統 (LIS) 和電子健康記錄 (EHR) 整合以及高級分析的投資，使醫療機構能夠在控制成本的同時應對不斷成長的檢測量。此外，居家診斷和直接面對消費者的檢測等新的檢測管道也促進了收入的成長。

總體而言，臨床實驗室服務市場仍以高交易量為特徵，但收入成長越來越與支付方合作、營運規模和技術採用相關，從而推動美國臨床實驗室服務市場在預測期結束前持續成長。

成長要素：美國醫療和診斷檢測服務市場

美國醫療和診斷檢測服務市場受益於多項結構性成長要素，預計這些因素將在整個預測期內維持市場需求。其中一個最重要的促進因素是臨床資訊學和醫療數據生成在早期研究、臨床開發和商業診斷領域的快速發展。不斷成長的數據量提升了整合診斷、預測分析、決策支援工具和伴隨診斷 (CDx) 的價值，從而強化了檢查室在藥物研發和臨床試驗中的作用。

醫生自營實驗室（POL）就地檢驗（POC​​T）能力的擴展正在加速臨床實驗室服務市場的技術應用。同時，消費者對遠端醫療平台、行動醫療應用和連網診斷設備等健康資訊科技解決方案日益成長的興趣，也推動了對便利、快速且經濟高效的檢測服務的需求。

另一個關鍵成長要素是基於次世代定序（NGS）的檢測方法在感染疾病、腫瘤和基因檢測領域的持續擴展。保險覆蓋範圍的擴大和檢測成本的下降正推動分子病理學服務的應用實現兩位數成長。

營運投資也正在改變美國臨床實驗室服務市場。對機器人、實驗室資訊系統 (LIS) 和電子健康記錄 (EHR) 整合以及人工智慧驅動的自動化投入的增加，提高了檢查室的吞吐量，同時也縮短了出結果時間並減少了對人工的依賴。端到端的數位化工作流程正成為內部檢查室和外部實驗室的優先事項。

最後，來自《病患准入與平價醫療法案》(PAMA) 和綜合支付模式的持續報銷壓力正促使檢查室向更高價值、以結果為導向的服務模式轉型。產業整合和垂直一體化，以及居家採血、行動診斷和零售檢測合作的成長，進一步擴大了服務覆蓋範圍，並推動了美國臨床實驗室服務市場的持續成長。

成長抑制因素：美國醫療和診斷檢測服務市場

美國醫療和診斷檢測服務市場面臨許多結構性限制因素，這些因素可能會在整個預測期內抑制其成長。其中一項最嚴峻的挑戰是美國食品藥物管理局 (FDA) 關於檢查室自建檢測 (LDT) 的最終規則，該規則將於 2024 年生效。這項法規將增加合規、檢驗和文件編製成本，對小規模和專業檢查室的影響尤其顯著。雖然大規模參考檢查室可能從中獲得相對優勢，但學術實驗室和醫院附屬檢查室將面臨更長的新週期和較慢的檢測方法推廣速度。

在整個臨床實驗室服務市場，人才短缺仍然是一個持續存在的阻礙因素。由於培訓計畫資金不足、人員流動率高以及人才引進有限，美國合格的臨床實驗室技術人員持續短缺。尤其是在醫院檢查室，日益嚴重的職業倦怠、加班成本和人事費用限制了其發展。雖然自動化和外包可以在一定程度上緩解這個問題，但它們無法完全彌補人才短缺。

資本密集度也是一項重大挑戰。臨床檢查室需要持續投資於分析設備、自動化平台和IT基礎設施。中小檢查室面臨利潤率低、投資回收期長和資金籌措管道有限等問題，而通貨膨脹和報銷率下降加劇了這些壓力。

此外，儘管電子健康記錄 (EHR) 整合已被強制要求，但高級分析和自動化技術的應用仍然滯後。互通性問題、中介軟體系統碎片化、資料孤島、網路安全風險持續阻礙營運效率。缺乏標準化的檢測申請和數據交換通訊協定進一步加重了行政負擔，導致計費延遲、索賠被拒，以及在多方付費和跨州檢查室網路中因違規處罰。

競爭格局：美國醫療與診斷檢測服務市場

美國醫療和診斷檢測服務市場呈現出高度分散但又日益整合的競爭格局，全國約有1500家獲得CLIA認證的實驗室，其中包括區域性和全國性獨立實驗室、醫院外包專案、參考實驗室和專業檢測服務提供者。美國臨床檢測服務市場的競爭主要受規模、合規性、服務範圍和營運效率等因素所驅動。

影響臨床實驗室服務市場差異化的關鍵競爭因素包括：是否符合CLIA和CAP標準、支付方的報銷率、檢測準確性、週轉時間、成本效益以及檢測項目的廣度。與電子健康記錄（EHR）系統的整合以及透過收購實現整合協同協同效應的能力，對於競爭定位也至關重要，尤其對於大規模全國性醫療機構而言。

最終用戶群包括醫院檢查室、醫生擁有的檢查室(POL)、獨立實驗室和參考實驗室以及專業檢測提供商，此外，零售診所、移動診斷中心、療養院和居家醫療機構也有需求，所有這些都擴大融入美國臨床實驗室服務市場的醫療保健服務模式中。

競賽模式主要由大規模全國性專業機構主導，例如 Labcorp、Quest Diagnostics、Exact Sciences、Natera、Sonic Healthcare USA、Myriad Genetics、Guardant Health、Mayo Clinic Laboratories 和 ARUP Laboratories。預計到 2024 年，排名前五的獨立參考實驗室 (IRL) 將占美國臨床檢測服務總收入的 46.3%，顯示市場高階集中度日益提高。

其他值得關注的公司包括 BioReference Laboratories、Northwell Health Labs、PathGroup 和 Aegis Sciences，以及克利夫蘭診所和約翰霍普金斯等學術醫院網路。

美國醫療和診斷檢測服務市場的分銷模式結合了醫院網路、集中式參考實驗室以及不斷擴展的用於檢體採集的宅配和數位化物流基礎設施。 2024年，Quest Diagnostics收購了Allina Health的部分檢測資產，增強了明尼蘇達州和威斯康辛州西部地區的檢測服務覆蓋範圍，並凸顯了該市場持續整合的趨勢。

目錄

發展機會：研究範圍

• 分析範圍
• 分割
• 臨床實驗室服務在醫療保健中的作用
• 綜合經營模式－實驗室作為一站式服務提供者
• 創新以增強臨床檢測服務

成長環境：美國臨床實驗室服務業的轉型

• 為什麼經濟成長變得越來越困難？
• 策略要務
• 三大策略要務對美國臨床實驗室服務業的影響

美國臨床實驗室服務生態系統

• 競爭環境

推動美國臨床實驗室服務業成長的因素

• 成長指標
• 成長促進因素
• 成長限制因素
• 預測考量
• 收入預測
• 收入預測分析
• 服務供應商的收入預測
• 服務供應商收入預測分析
• 按服務分類的收入預測
• 按服務分類的收入預測分析
• 美國臨床實驗室服務定價分析
• 美國臨床實驗室服務按應用領域分類的定價分析（2024 年）
• 美國化驗服務應用佔有率細分
• 美國監管和報銷的關鍵趨勢（2020-2025 年）
• 美國監管環境分析－2024年及以後
• 2024年美國健康保險展望概述
• 聯邦醫療保險和醫療補助醫院醫療費用支出
• 收益分成
• 收入佔有率分析－競爭對手
• 按付款人類型分類的 IRL 收入佔有率
• 主要企業提供的競爭格局和參數
• 重要活動

美國臨床實驗室服務領域的成長機會

• 成長機會 1：除急性病和腫瘤檢測之外的專科和高級檢測
• 成長機會2：建構去中心化的居家診斷生態系統，提升診斷的可近性與速度
• 成長機會3：人工智慧驅動的數位病理學和高通量診斷工作流程自動化

附錄與後續步驟

Fueled by Specialty Testing Expansion, Digital Workflow Innovation, and Value-Based Healthcare Demands

The clinical laboratory testing industry will continue to experience growth in testing volumes due to the aging of the US population, patient awareness of the benefits of laboratory testing, test cost reductions, the development of advanced and specialized tests for disease detection and management, the growing awareness of early detection and prevention as a way to lower healthcare costs, and continued research and development in genetics, genomics, and personalized medicine.

The United States spends approximately 18% of its GDP on healthcare. Healthcare value chain participants face dynamic environments that several trends impact, including the rise in the aging population, chronic disease burden, regulatory challenges, integration across the care continuum, migration to value-based and accountable care models, payer and provider consolidation, new and increased access to data, innovation, and technology, and increasing levels of consumer engagement and expectations.

As a result of post-pandemic test normalization, increased outpatient volume, and the integration of advanced molecular and genomic assays into routine care, growth momentum continues to accelerate through 2024 and 2025. From 2026 onward, growth moderates toward 4 to 5%, in line with the updated forecast trajectory, as the industry settles around payer-driven usage restrictions and high-throughput efficiency. Although the Protecting Access to Medicare Act (PAMA) continues to exert price pressure, payer reimbursements are increasingly linked to clinical utility and test value. To preserve profits, this forces labs-especially those affiliated with hospitals and mid-tier regional players-to focus on operational scalability, test menu optimization, and digital workflow efficiency to run profitably.

Report Summary: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market was valued at USD 130.88 billion in 2024 and is projected to reach USD 175.13 billion by 2030, growing at a CAGR of 5.0% from 2024 to 2030. Market growth is driven by rising test volumes associated with an aging population, increasing prevalence of chronic diseases, and the expanding role of laboratory diagnostics in preventive and value-based care models.

Key Market Trends & Insights

• Independent and reference laboratories account for a significant share of testing volumes in the clinical laboratory services market, supported by national logistics networks and broad test menus.
• In the US Clinical Laboratory Services Market, demand for molecular diagnostics, oncology testing, and genetic assays is increasing alongside routine diagnostic testing.
• Automation, LIS-EHR integration, and AI-enabled workflow optimization are improving turnaround times and operational efficiency across large and mid-sized laboratories.
• The US Clinical Laboratory Service Market is experiencing continued consolidation as large national laboratories expand through acquisitions and hospital outreach partnerships.
• Retail clinics, mobile diagnostics, and home-based sample collection models are expanding patient access and convenience, supporting incremental test utilization.

Market Size & Forecast

• 2024 Market Size: USD 130.88 Billion
• 2030 Projected Market Size: USD 175.13 Billion
• CAGR (2024-2030): 5.0%
• United States: Single-country market with nationwide laboratory coverage

The continued reliance of the U.S. healthcare system on diagnostic testing, combined with technology adoption and service model innovation, is expected to support sustained growth in the U.S. Medical and Diagnostic Laboratory Services Market through the forecast period.

Market Overview & Trends: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market underpins nearly every clinical decision across the healthcare continuum. Laboratory testing supports screening, diagnosis, therapy selection, and disease monitoring, making the clinical laboratory services market indispensable to modern medicine. Demand continues to rise due to population aging, increasing chronic disease burden, and expanded utilization of diagnostic testing in value-based care models.

A major structural trend shaping the US Clinical Laboratory Services Market is the shift toward specialized and high-complexity testing. Molecular diagnostics, genomics, oncology assays, and companion diagnostics are increasingly used to guide personalized treatment strategies. While routine testing continues to provide volume stability, specialty diagnostics are driving incremental growth and clinical relevance.

Automation and digitalization are transforming laboratory operations. Advanced robotics, laboratory information systems (LIS), and artificial intelligence-enabled workflow tools are improving turnaround times and reducing labor dependency. These investments are particularly critical as workforce shortages persist across the U.S. Medical and Diagnostic Laboratory Services Market.

Another important trend is the centralization of testing. Independent and reference laboratories are capturing a growing share of outsourced testing volumes due to economies of scale and broad test menus. Consolidation enables cost efficiency but also intensifies competition within the US Clinical Laboratory Service Market.

Consumerization of healthcare is also influencing demand. Retail clinics, mobile diagnostics, and home-based sample collection are expanding access to routine testing and preventive care. These models complement traditional hospital-based services and reshape patient engagement across the clinical laboratory services market.

Overall, the market is evolving toward a more automated, data-driven, and patient-centric diagnostic ecosystem.

Scope of Analysis: U.S. Medical and Diagnostic Laboratory Services Market

This analysis examines the U.S. Medical and Diagnostic Laboratory Services Market, focusing on laboratory-based testing services delivered within the United States. The study evaluates diagnostic testing performed on blood, tissue, urine, and other biological specimens to support clinical decision-making across preventive, diagnostic, and therapeutic applications.

The scope includes hospital-based laboratories, independent and reference laboratories, physician office laboratories, and emerging retail and home-testing models. Both routine and specialized testing services are covered within the US Clinical Laboratory Services Market, while laboratory equipment manufacturing and reagent sales are excluded.

The study period spans recent historical years through 2030, with 2024 as the base year and 2030 as the forecast endpoint. Market sizing and forecasts are presented in U.S. dollars.

Methodologically, the analysis integrates secondary research, healthcare utilization data, regulatory review, and expert insights. Market forecasts reflect testing volume trends, reimbursement dynamics, and structural changes across the clinical laboratory services market. Segmentation-level revenue estimates are intentionally excluded to maintain analytical consistency.

Market Segmentation Analysis: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market is segmented by service provider type and testing service category, reflecting the diverse operational models and clinical roles within the broader clinical laboratory services market.

Segmentation by Service Providers

By provider type, the US Clinical Laboratory Services Market comprises hospital-based laboratories, physician-owned laboratories (POLs), independent and reference laboratories, specialized laboratories, and other laboratory settings.

Hospital-based laboratories perform the highest volume of tests and are directly integrated into hospital systems, supporting inpatient care, emergency diagnostics, and complex clinical workflows. These laboratories are typically attached to large healthcare institutions and academic medical centers, enabling rapid turnaround times and close coordination with clinical teams.

Physician-owned laboratories (POLs) operate within physician offices and specialty practices such as urology, gynecology, and endocrinology. POLs represent the most common laboratory type by number, although they account for less than 10% of total test volumes. These facilities focus on low-volume, routine, and point-of-care tests that deliver immediate results. Larger POL networks often forward samples to centralized laboratories for advanced testing.

Independent, reference, and specialized laboratories operate across wide geographic regions and manage multiple laboratory facilities. Reference laboratories provide comprehensive test menus and handle high-throughput volumes, while specialized laboratories focus on advanced diagnostics such as oncology, genetics, and molecular testing. These providers play a central role in the US Clinical Laboratory Service Market, supporting outsourced testing for hospitals and POLs.

Other laboratories include retail clinics, mobile diagnostic centers, nursing homes, and home health agencies. These settings primarily support routine and preventive testing. Many services in this category are paid out-of-pocket and are not fully reimbursed under Medicare, contributing modestly to overall healthcare revenue.

Segmentation by Testing Services

By service type, the clinical laboratory services market is divided into routine testing services and specialized testing services.

Routine testing services include commonly performed diagnostic procedures such as blood chemistry panels, complete blood counts, and urine analysis. These tests form the backbone of diagnostic volume across the U.S. Medical and Diagnostic Laboratory Services Market.

Specialized testing services encompass high-end diagnostics such as cytogenetics, molecular diagnostics, next-generation sequencing (NGS), and whole-exome sequencing (WES). Semi-specialized services, including coagulation studies, autoimmune testing, and cancer biomarker assays, also fall within this segment. Growth in specialized testing reflects increasing demand for precision medicine and advanced clinical decision support.

Revenue & Spending Forecast: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market continues to evolve as automation, consolidation, and the shift toward value-based care reshape industry economics. According to the revenue forecast, the market generated USD 130.88 billion in 2024 and is projected to reach USD 175.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.0% during 2024-2030. This steady expansion underscores the essential role of laboratory testing in clinical decision-making across the U.S. healthcare system.

Revenue growth in the US Clinical Laboratory Services Market is supported by rising test volumes driven by an aging population, increasing prevalence of chronic diseases, and expanded utilization of diagnostic testing in preventive and longitudinal care. At the same time, the market is undergoing structural change as laboratories adapt to margin pressures resulting from PAMA-driven reimbursement reductions, rising labor costs, and tighter regulatory oversight of laboratory-developed tests (LDTs).

Large national and hospital-affiliated laboratories are increasingly expanding through mergers, digital integration, and AI-enabled process automation to improve operational efficiency and scale. Investments in automation, LIS-EHR integration, and advanced analytics are enabling providers to manage higher volumes while controlling costs. Additionally, new access channels-such as home-based diagnostics and consumer-oriented testing-are contributing to incremental revenue growth.

Overall, while the clinical laboratory services market remains high-volume in nature, revenue expansion is increasingly linked to payer alignment, operational scale, and technology adoption, positioning the US Clinical Laboratory Service Market for sustained growth through the end of the forecast period.

Growth Drivers: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market is supported by multiple structural growth drivers that are expected to sustain demand through the forecast period. One of the most significant drivers is the rapid expansion of clinical informatics and healthcare data generation across early-stage research, clinical development, and commercial diagnostics. Growing data volumes are increasing the value of integrated diagnostics, predictive analytics, decision-support tools, and companion diagnostics (CDx), strengthening the role of laboratories in drug development and clinical trials.

Technology adoption within the clinical laboratory services market is accelerating as physician-owned laboratories (POLs) expand point-of-care testing (POCT) capabilities. At the same time, rising consumer interest in health IT solutions-such as telemedicine platforms, mobile health applications, and connected diagnostic devices-is driving demand for convenient, faster, and cost-effective testing services.

Another major growth driver is the continued expansion of next-generation sequencing (NGS)-based panels across infectious disease, oncology, and genetic testing. Improvements in payer coverage and declining test costs are enabling broader adoption of molecular pathology services at double-digit growth rates.

Operational investments are also reshaping the US Clinical Laboratory Services Market. Increased spending on robotics, LIS-EHR integration, and AI-driven automation is improving laboratory throughput while reducing turnaround times and workforce dependency. End-to-end digital workflows are becoming a priority for both hospital-based and reference laboratories.

Finally, ongoing reimbursement pressure under PAMA and bundled payment models is pushing laboratories toward higher-value, outcome-based service models. Industry consolidation and vertical integration, combined with the growth of at-home phlebotomy, mobile diagnostics, and retail testing partnerships, are further expanding access and driving sustained growth across the US Clinical Laboratory Service Market.

Growth Restraints: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market faces several structural restraints that may moderate growth through the forecast period. One of the most significant challenges is the implementation of the FDA's Final Rule on Laboratory Developed Tests (LDTs) in 2024. The regulation has increased compliance, validation, and documentation costs, disproportionately impacting small and specialized laboratories. While large reference laboratories may gain a relative advantage, academic and hospital-based labs face longer innovation cycles and delayed test adoption.

Workforce constraints remain a persistent restraint across the clinical laboratory services market. The United States continues to experience a shortage of qualified medical technologists due to underfunded training programs, high retirement rates, and limited new workforce entry. Rising burnout, overtime expenses, and staffing costs are restricting growth, particularly for hospital-based laboratories. Although automation and outsourcing provide partial relief, they do not fully offset labor shortages.

Capital intensity represents another key challenge. Clinical laboratories must continuously invest in analyzers, automation platforms, and IT infrastructure. Smaller and mid-tier laboratories face low margins, extended return-on-investment periods, and limited access to funding, pressures that are amplified by inflation and declining reimbursement rates.

In addition, slow adoption of advanced analytics and automation persists despite mandatory EHR integration. Interoperability issues, fragmented middleware systems, data silos, and cybersecurity risks continue to limit operational efficiency. The absence of standardized test ordering and data exchange protocols further increases administrative burdens, leading to billing delays, claim rejections, and compliance penalties across multi-payer and multi-state laboratory networks.

Competitive Environment: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market is characterized by a highly fragmented yet consolidating competitive environment, comprising approximately 1,500 CLIA-certified laboratories nationwide. These include regional and national independent laboratories, hospital outreach programs, reference laboratories, and specialty testing providers. Competition within the US Clinical Laboratory Services Market is driven by scale, regulatory compliance, service breadth, and operational efficiency.

Key competitive factors shaping differentiation across the clinical laboratory services market include compliance with CLIA and CAP standards, payer reimbursement rates, test accuracy, turnaround time, cost effectiveness, and the breadth of test menus. Integration with electronic health record (EHR) systems and the ability to realize consolidation synergies through acquisitions also play a critical role in competitive positioning, particularly for large national providers.

End-user verticals span hospital-based laboratories, physician-owned laboratories (POLs), independent and reference laboratories, and specialized testing providers. Additional demand is generated by retail clinics, mobile diagnostic centers, nursing homes, and home health agencies, all of which are increasingly integrated into care delivery models across the US Clinical Laboratory Service Market.

The competitive landscape is led by large national and specialty players, including Labcorp, Quest Diagnostics, Exact Sciences, Natera, Sonic Healthcare USA, Myriad Genetics, Guardant Health, Mayo Clinic Laboratories, and ARUP Laboratories. Collectively, the top five independent reference laboratories (IRLs) accounted for an estimated 46.3% of total U.S. clinical laboratory services revenue in 2024, highlighting increasing concentration at the top end of the market.

Other notable participants include BioReference Laboratories, Northwell Health Labs, PathGroup, Aegis Sciences, as well as academic hospital networks such as Cleveland Clinic and Johns Hopkins.

Distribution across the U.S. Medical and Diagnostic Laboratory Services Market combines hospital-based networks, centralized reference laboratories, and expanding courier and digital logistics infrastructure for specimen collection. In 2024, Quest Diagnostics acquired select laboratory assets from Allina Health, enhancing access to laboratory services across Minnesota and western Wisconsin and underscoring ongoing consolidation trends within the market.

Table of Contents

Growth Opportunities: Research Scope

• Scope of Analysis
• Segmentation
• The Role of Clinical Laboratory Services in Healthcare
• Holistic Business Model-Laboratories as 1-Stop-Shop Service Providers
• Innovations Enhancing Clinical Laboratory Services

Growth Environment: Transformation in United States Clinical Laboratory Services Industry

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the United States Clinical Laboratory Services Industry

Ecosystem in United States Clinical Laboratory Services Industry

• Competitive Environment

Growth Generator in United States Clinical Laboratory Services Industry

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Forecast Considerations
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Service Providers
• Revenue Forecast Analysis by Service Providers
• Revenue Forecast by Services
• Revenue Forecast Analysis by Services
• US Clinical Laboratory Services Pricing Analysis
• US Clinical Laboratory Services Pricing Analysis by Application, 2024
• US Breakdown of Application Shares in Laboratory Services
• United States Key Regulatory and Reimbursement Environment Developments 2020-2025
• United States Regulatory Landscape Analysis-2024 Onwards
• US Health Insurance Landscape-2024 Overview
• Medicare and Medicaid Spending on Hospital Care
• Revenue Share
• Revenue Share Analysis-Competitor
• Revenue Share by Type of Payer in IRLs
• Competitive Landscape, Top Players Offering Parameters
• Notable Activities

Growth Opportunity Universe in United States Clinical Laboratory Services

• Growth Opportunity 1: Specialized and Advanced Testing Beyond Acute and Oncology Testing
• Growth Opportunity 2: Decentralized and Home-Based Diagnostics Ecosystem for Enhanced Access and Speed
• Growth Opportunity 3: AI-Driven Digital Pathology and Workflow Automation for High-Volume Diagnostics

Appendix & Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits
• Legal Disclaimer